Home › Idiopathic Hypersomnia › Texas
Idiopathic Hypersomnia clinical trials in Texas
7 studies for Idiopathic Hypersomnia are looking for participants at sites in Texas.
Cities in Texas
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
- Aayus Research, Austin
- Southwest Family Medicine Associates, Dallas
- DSM Research LLC, Frisco
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07500090A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
- Takeda Site 20, Austin
- Takeda Site 3, San Antonio
RecruitingPhase 2/3
Ages 18 to 71 · All sexes · Updated Nov 5, 2026 · NCT07646678A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
- Alkermes Investigational Site, Austin
- Alkermes Investigational Site, Dallas
- Alkermes Investigational Site, San Antonio
- and 1 more
RecruitingPhase 2/3
Ages 18 to 70 · All sexes · Updated Oct 9, 2026 · NCT06767683A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
- Future Search Trials - Austin Neurology, Austin
- FutureSearch Trials of Dallas, Dallas
- Tricoastal Narcolepsy and Sleep Disorders Center, Sugar Land
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 8, 2026 · NCT07625280A Study of TAK-360 in Adults With Idiopathic Hypersomnia
- Takeda Site 18, San Antonio
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 15, 2026 · NCT06812078A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Austin, Texas, Austin
- El Paso, TX, El Paso
- San Antonio, Texas, San Antonio
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Apr 27, 2026 · NCT06752668A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
- Austin, Texas, Austin
- El Paso, Texas, El Paso
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Apr 16, 2026 · NCT07096674From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.